PainPhase 2/3NCT02151682
A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain
A Phase 2/3 study testing Tapentadol prolonged release and Morphine prolonged release in people with Pain, run by Grünenthal GmbH at 23 sites in 10 countries.
Trial summary
Tapentadol has already been studied in adults. This study is needed to find out if tapentadol works and is safe to use in children and adolescents with long-term pain. Read more about this study
- Who is it for?
- Ages 6 to 17 years
- Conditions the study is for
- Pain
- What is being tested?
- Tapentadol prolonged release and Morphine prolonged release
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 73 participants
- Where
- 23 sitesin 10 countries
- Study dates
- 29 Apr 2015to 15 Oct 2018
- Phase
- Phase 2/3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Part 1 - Randomized to open-label, active comparator controlled treatment
- Participants were eligible for the study at enrollment if all the following applied:
- Informed consent (if applicable assent) obtained.
- Male or female participant at least 6 years of age at the Enrollment Visit and less than 18 years of age on Day 14.
- Participant has an underlying long-term pain condition (e.g., cancer, chronic disease, planned or performed surgery) that is, according to the judgment of the investigator, expected to require a twice-daily prolonged release opioid treatment until at least the end of the 14-day Treatment Period.
- Participant can swallow tablets of appropriate size.
Show all 18Show fewer
- Participant is able to participate in the study as planned and willing to comply with the requirements of the protocol including refraining from drinking beverages containing alcohol and recreational intake of drugs while on study medication.
- Participants had to satisfy the following criteria before allocation to treatment:
- Less than 18 years of age.
- No opioid intake or last calculated morphine equivalent dose of less than 3.5 mg/kg per day.
- Participant has a body weight of at least 17.5 kg.
- If a female of childbearing potential (post menarchal and not surgically incapable of childbearing) and sexually active, must practice an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double barrier method, contraceptive patch) before allocation to study medication until the end of intake of study medication.
- If a female and post menarchal or older than 12 years, has a negative urine pregnancy test on the day before or on the day of allocation to study medication.
- Part 2
- Inclusion criteria for the Tapentadol Open-label extension period:
- Participant has completed the 14-day Treatment Period.
- Participant is still in need of prolonged release opioid treatment.
- Participant does not meet any of the compulsory discontinuation criteria.
Who cannot join
- Participants were not eligible for the study if any of the following applied.
- The following was checked at enrollment:
- Has been previously enrolled in this study or a previous study with tapentadol.
- Has a clinically relevant history of hypersensitivity, allergy, or contraindication to morphine or tapentadol or any ingredient, including galactose intolerance (see investigator's brochure for tapentadol prolonged-release [PR] and summary of product characteristics for morphine PR), or naloxone.
- History or current condition of any one of the following:
- Seizure disorder or epilepsy.
Show all 34Show fewer
- Serotonin syndrome.
- Traumatic or hypoxic brain injury, brain contusion, stroke, transient ischemic attack, intracranial hematoma, posttraumatic amnesia, brain neoplasm, or episode(s) of more than 24 hours duration of unconsciousness.
- History or current condition of any one of the following:
- Moderate to severe renal or hepatic impairment.
- Abnormal pulmonary function or clinically relevant respiratory disease (e.g., acute or severe bronchial asthma, hypercapnia)
- Complex regional pain syndrome.
- A pain indication with a strong psycho-somatic component that, in the judgment of the investigator, is unlikely to respond to opioids.
- History of alcohol or drug abuse in the investigator's judgment, based on history and physical examination. Drugs of abuse detected in urine screen unless explained by allowed concomitant medication
- Participant has:
- A clinically relevant abnormal electrocardiogram.
- Signs of pre-excitation syndrome.
- Brugada's syndrome.
- QT or corrected QT (QTcF, Fridericia) interval greater than 470 ms.
- Any surgery scheduled during the first 14 days of the study that is expected to require post-surgical intensive care unit (ICU) treatment, or that requires post-surgical parenteral pain-treatment, or may, affect the safety of the participant.
- Participant is not able to understand and comply with the protocol as appropriate for the age of the participant or participant is cognitively impaired in the investigator's judgment such that they cannot comply with the protocol.
- Participant, parent or the legal representative is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, or family member of the employees or the investigator.
- The following was checked at the enrollment and the allocation visits:
- Has a concomitant disease or disorder (e.g., endocrine, metabolic, neurological, psychiatric, infection) that in the opinion of the investigator may affect or compromise participant safety during the study participation.
- Pancreatic/biliary tract disease (e.g., pancreatitis) or paralytic ileus.
- Intake of forbidden concomitant medication/use of forbidden therapies (see synopsis section Concomitant medications/therapies).
- Female participant is breastfeeding a child.
- The following was checked at the allocation to treatment visit:
- Has received a drug or used a medical device not approved for human use within 30 days prior to visit.
- Based on data from the local laboratory, one or more of:
- Total serum bilirubin greater than 2.0 mg/dL.
- Serum albumin less than 2.8 g/dL.
- Aspartate transaminase or alanine transaminase greater than 5 times upper limit of normal.
- Based on data from the local laboratory, creatinine clearance less than 30 mL/min per 1.73 m2 (calculated according to a formula that is appropriate for the respective age group).
Trial locations and contacts
23 sites in 10 countries.
23 sites in 10 countries
France7 sites
FR008
Amiens, 80054
FR004
Brest, 29609
FR002
Lille, 59020
FR006
Lyon, 69008
FR005
Nice, 06200
FR001
Vandœuvre-lès-Nancy, 54500
FR003
Villejuif, 94805
Bulgaria4 sites
BG005
Pleven, 5800
BG004
Plovdiv, 4001
BG001
Sofia, 1606
BG006
Sofia, 1606
United Kingdom3 sites
GB005
Leeds, LS1 3EX
GB003
Manchester, M13 9WL
GB006
Sheffield, S10 2TH
About this study
Official title: An Open-label Trial, Enrolling Subjects Aged 6 Years to Less Than 18 Years Suffering From Pain Requiring Prolonged Release Opioid Treatment, to Evaluate the Safety and Efficacy of Tapentadol PR Versus Morphine PR, Followed by an Open-label Extension
Tapentadol has already been studied in adults. This study is needed to find out if tapentadol works and is safe to use in children and adolescents with long-term pain.
Read the detailed description
During the first 2 weeks of the study (Part 1), participants were given either tapentadol or morphine prolonged-release (PR) tablets. Assignment was done randomly (like tossing a coin). The participant and the caregiver knew which medication the child was taking. The primary endpoint was based on data collected in Part 1 of this study.
If eligible and willing, participants from Part 1 could enter a 12 month follow-up period (Part 2). In Part 2 of this study, participants were either treated with tapentadol PR tablets or entered observations arms where they were not treated at all or with standard of care.
- Conditions
- Pain
- Being tested
- Tapentadol prolonged release, Morphine prolonged release
- Keywords
- chronic pain, opioid
- Medical subject headings
- Pain, Chronic Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tapentadol prolonged releaseDrug
Also called Palexia®, Nucynta®, Yantil®
Morphine prolonged releaseDrug
| Study group | Role | What they receive |
|---|---|---|
| Morphine prolonged-release (Part 1) | Active comparator | 10 milligram (mg) or 30 mg tablets were taken orally twice daily. Starting doses varied from 10 to 40 mg morphine PR twice daily depending on participant's weight; if necessary, doses were gradually increased up to a maximum dose defined per weight group.
The highest dose defined for participants weighing 55 kg and more was 200 mg per day. Receives: Drug: Morphine prolonged release |
| Tapentadol prolonged-release (Part 1) | Experimental | 25 mg or 100 mg tablets were taken orally twice daily. Starting doses varied from 25 to 100 mg tapentadol PR twice daily depending on participant's weight. If necessary, doses were gradually increased up to a maximum dose defined per weight group.
The highest dose defined for participants weighing 55 kg and more was 500 mg per day. Receives: Drug: Tapentadol prolonged release |
| Tapentadol in Part 2 after Tapentadol or Morphine in Part 1 | Experimental | Participants on tapentadol PR in Part 1 of the study continued on the current dose of tapentadol PR in Part 2 and if necessary could modify their tapentadol PR dosage. Participants who were randomized to morphine PR in Part 1 of the study were rotated to tapentadol PR in Part 2 with 70 percent of their current morphine equivalent dose or lower. The dosage could be increased gradually up to approximately 4.5 mg/kg body weight tapentadol PR twice daily. Receives: Drug: Tapentadol prolonged release |
| Observation Period after Tapentadol in Part 1 | No intervention | Participants who completed tapentadol PR in Part 1 of the study or discontinued tapentadol treatment early in Part 1 could continue directly in the observation period in Part 2 for up to 12 months (with standard-of-care treatment if needed). |
| Observation Period after Morphine in Part 1 | No intervention | Participants who completed morphine PR treatment in Part 1 of the study or discontinued early from morphine treatment in Part 1 could continue directly in the observation period in Part 2 (with standard-of-care treatment if needed). |
| Observation Period after Tapentadol in Part 2 | No intervention | Participants who completed tapentadol PR or morphine PR treatment in Part 1 of the study could enter the Observation Period for up to 12 months (with standard-of-care treatment if needed) after they had discontinued from tapentadol PR treatment in Part 2. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants Classified as Responder (Part 1)
The proportion of participants classified as responders was assessed and compared between the treatment groups.
A participant was defined as responder if both of the following criteria were met:
- Completion of the 14-day Treatment Period (Part 1).
- One of the following calculated from the scheduled pain assessments ("pain right now") documented during the last 3 days of the Treatment Period:
- Average pain less than 50 on a visual analog scale (VAS, range 0 [no pain] to 100 [pain as bad as it could be]) for participants aged 12 years to less than 18 years; or less than 5 on the Faces Pain Scale-revised (FPS-R, range 0 [no pain] and 10 [very much pain]) for participants aged 6 years to less than 12 years.
- Average reduction from baseline of pain greater than or equal to 20 on a VAS for participants aged 12 years to less than 18 years; or greater than or equal to 2 on the FPS-R for participants aged 6 years to less than 12 years.
Measured: From Day 1 up to Day 14 (End of Part 1)
Secondary outcomes (2)
Extent of Constipation (Part 1)
Constipation was assessed using the modified constipation assessment scale (mCAS). This is an 8-item questionnaire where the observer has scored constipation on a nominal scale (no Problem [score 0], some problem [score 1] or severe Problem [score 2]). The response to an item could also be scored as "unable to assess".
The Total Score can vary from 0-16; the higher the Total Score the higher the extent of constipation. A positive change from Day 1 to Day 14 indicates a worsening, a negative change an improvement.
Measured: From Day 1 to Day 14 (End of Part 1)
Tolerability Over the Complete Trial Period
Tolerability was assessed by the number of participants with exactly 1 to more than 5 treatment emergent adverse events (TEAE) by treatment group during the different trial periods, on a participant level.
In addition, tolerability was assessed by the number of participants with TEAEs which were considered by the investigator to be at least possibly related to the treatment the participant received.
Measured: Part 1: Day 1 (Start of Part 1) to Day 14; Part 2: Day 15 to Day 379 (End of Part 2)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 May 2014 (estimated)
- Study start29 Apr 2015
- Primary completion18 Oct 2017
- Study completion15 Oct 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- There were 2 arms in Part 1: Randomization was carried out in blocks and in a 2:1 ratio (tapentadol PR to morphine PR). Participants were stratified using interactive response technology: by age group (6 years to less than 12 years and 12 years to less than 18 years, at the second visit \[Allocation Visit\]) so that at least 25% of participants were in the younger age group, and by underlying pain condition (cancer/non-cancer-related pain). There were 4 arms in Part 2: The investigators/participants decided if participants from Part 1 switched to or continued on tapentadol PR (tapentadol arm) or if they received no treatment/standard of care treatment if needed (2 direct observation arms following treatment in Part 1 and 1 observation arm after initial treatment with tapentadol in Part 2).
- Masking
- None (open label)
- Enrolment
- 73 participants (actual)
Sponsor and investigators
- Lead sponsor
- Grünenthal GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Director Clinical Trials, Study director, Grünenthal GmbH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02151682
- Sponsor's protocol ID
- KF5503-66
- Other IDs
- 2012-004360-22, U1111-1154-4572
- Status last verified
- Aug 2019
- First submitted
- 28 May 2014
- Last updated
- 12 Sep 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Information available on the Grünenthal Web Site (see URL below for details)
Study at a glance
From the registry record, last updated by the sponsor on 12 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label Trial, Enrolling Subjects Aged 6 Years to Less Than 18 Years Suffering From Pain Requiring Prolonged Release Opioid Treatment, to Evaluate the Safety and Efficacy of Tapentadol PR Versus Morphine PR, Followed by an Open-label Extension
- ClinicalTrials.gov ID
- NCT02151682
- Acronym / sponsor ID
- KF5503-66
- Conditions
- Pain
- Keywords
- chronic pain, opioid
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 73 participants (actual)
- Lead sponsor
- Grünenthal GmbHIndustry (pharma, biotech, devices)
- Study start
- 29 Apr 2015 (actual)
- Primary completion
- 18 Oct 2017 (actual)
- Study completion
- 15 Oct 2018 (actual)
- First posted
- 30 May 2014 (estimated)
- Results
- Posted 12 Sep 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Tapentadol has already been studied in adults. This study is needed to find out if tapentadol works and is safe to use in children and adolescents with long-term pain.
Detailed description
During the first 2 weeks of the study (Part 1), participants were given either tapentadol or morphine prolonged-release (PR) tablets. Assignment was done randomly (like tossing a coin). The participant and the caregiver knew which medication the child was taking. The primary endpoint was based on data collected in Part 1 of this study.
If eligible and willing, participants from Part 1 could enter a 12 month follow-up period (Part 2). In Part 2 of this study, participants were either treated with tapentadol PR tablets or entered observations arms where they were not treated at all or with standard of care.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 6
- Model description
- There were 2 arms in Part 1: Randomization was carried out in blocks and in a 2:1 ratio (tapentadol PR to morphine PR). Participants were stratified using interactive response technology: by age group (6 years to less than 12 years and 12 years to less than 18 years, at the second visit [Allocation Visit]) so that at least 25% of participants were in the younger age group, and by underlying pain condition (cancer/non-cancer-related pain). There were 4 arms in Part 2: The investigators/participants decided if participants from Part 1 switched to or continued on tapentadol PR (tapentadol arm) or if they received no treatment/standard of care treatment if needed (2 direct observation arms following treatment in Part 1 and 1 observation arm after initial treatment with tapentadol in Part 2).
| Arm | Type | Receives |
|---|---|---|
| Morphine prolonged-release (Part 1) | Active comparator | Drug: Morphine prolonged release10 milligram (mg) or 30 mg tablets were taken orally twice daily. Starting doses varied from 10 to 40 mg morphine PR twice daily depending on participant's weight; if necessary, doses were gradually increased up to a maximum dose defined per weight group. The highest dose defined for participants weighing 55 kg and more was 200 mg per day. |
| Tapentadol prolonged-release (Part 1) | Experimental | Drug: Tapentadol prolonged release25 mg or 100 mg tablets were taken orally twice daily. Starting doses varied from 25 to 100 mg tapentadol PR twice daily depending on participant's weight. If necessary, doses were gradually increased up to a maximum dose defined per weight group. The highest dose defined for participants weighing 55 kg and more was 500 mg per day. |
| Tapentadol in Part 2 after Tapentadol or Morphine in Part 1 | Experimental | Drug: Tapentadol prolonged releaseParticipants on tapentadol PR in Part 1 of the study continued on the current dose of tapentadol PR in Part 2 and if necessary could modify their tapentadol PR dosage. Participants who were randomized to morphine PR in Part 1 of the study were rotated to tapentadol PR in Part 2 with 70 percent of their current morphine equivalent dose or lower. The dosage could be increased gradually up to approximately 4.5 mg/kg body weight tapentadol PR twice daily. |
| Observation Period after Tapentadol in Part 1 | No intervention | –Participants who completed tapentadol PR in Part 1 of the study or discontinued tapentadol treatment early in Part 1 could continue directly in the observation period in Part 2 for up to 12 months (with standard-of-care treatment if needed). |
| Observation Period after Morphine in Part 1 | No intervention | –Participants who completed morphine PR treatment in Part 1 of the study or discontinued early from morphine treatment in Part 1 could continue directly in the observation period in Part 2 (with standard-of-care treatment if needed). |
| Observation Period after Tapentadol in Part 2 | No intervention | –Participants who completed tapentadol PR or morphine PR treatment in Part 1 of the study could enter the Observation Period for up to 12 months (with standard-of-care treatment if needed) after they had discontinued from tapentadol PR treatment in Part 2. |
Who may qualify
- Ages
- 6 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (18 listed)
- Part 1 - Randomized to open-label, active comparator controlled treatment
- Informed consent (if applicable assent) obtained.
- Male or female participant at least 6 years of age at the Enrollment Visit and less than 18 years of age on Day 14.
- Participant has an underlying long-term pain condition (e.g., cancer, chronic disease, planned or performed surgery) that is, according to the judgment of the investigator, expected to require a twice-daily prolonged release opioid treatment until at least the end of the 14-day Treatment Period.
- Participant can swallow tablets of appropriate size.
Key exclusion criteria (34 listed)
- Participants were not eligible for the study if any of the following applied.
- Has been previously enrolled in this study or a previous study with tapentadol.
- Has a clinically relevant history of hypersensitivity, allergy, or contraindication to morphine or tapentadol or any ingredient, including galactose intolerance (see investigator's brochure for tapentadol prolonged-release [PR] and summary of product characteristics for morphine PR), or naloxone.
- History or current condition of any one of the following:
- History or current condition of any one of the following:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tapentadol prolonged releaseAlso: Palexia®, Nucynta®, Yantil® | Drug | Tapentadol in Part 2 after Tapentadol or Morphine in Part 1, Tapentadol prolonged-release (Part 1) |
| Morphine prolonged release | Drug | Morphine prolonged-release (Part 1) |
Primary outcome
Number of Participants Classified as Responder (Part 1)
Time frame: From Day 1 up to Day 14 (End of Part 1)
The proportion of participants classified as responders was assessed and compared between the treatment groups. A participant was defined as responder if both of the following criteria were met: * Completion of the 14-day Treatment Period (Part 1). * One of the following calculated from the scheduled pain assessments ("pain right now") documented during the last 3 days of the Treatment Period: * Average pain less than 50 on a visual analog scale (VAS, range 0 [no pain] to 100 [pain as bad as it could be]) for participants aged 12 years to less than 18 years; or less than 5 on the Faces Pain Scale-revised (FPS-R, range 0 [no pain] and 10 [very much pain]) for participants aged 6 years to less than 12 years. * Average reduction from baseline of pain greater than or equal to 20 on a VAS for participants aged 12 years to less than 18 years; or greater than or equal to 2 on the FPS-R for participants aged 6 years to less than 12 years.
2 secondary outcomes
Extent of Constipation (Part 1)
Time frame: From Day 1 to Day 14 (End of Part 1)
Tolerability Over the Complete Trial Period
Time frame: Part 1: Day 1 (Start of Part 1) to Day 14; Part 2: Day 15 to Day 379 (End of Part 2)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Sep 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Yes. Information available on the Grünenthal Web Site (see URL below for details)
Related trials for Pain
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Recruiting
Empowered Relief® for Cancer Survivors With Chronic Pain
Chronic Pain Due to Cancer, Pain Catastrophizing
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Effects of Hip Hinge Exercises on Pain, Range of Motion and Functional Disability in Non-specific Low Back Pain.
Low Back Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Director Clinical Trials study director
Grünenthal GmbH
23 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Tapentadol prolonged release and Morphine prolonged release in people with Pain, run by Grünenthal GmbH at 23 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 34 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 23 sites in France, Bulgaria, United Kingdom, Chile, Portugal and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 12 Sep 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants Classified as Responder (Part 1) (time frame: From Day 1 up to Day 14 (End of Part 1)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2019.